Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib

Leukemia. 2014 Apr;28(4):976-7. doi: 10.1038/leu.2013.320. Epub 2013 Oct 30.

Authors

K Mayer¹, G H Gielen², W Willinek³, M C Müller⁴, D Wolf¹

Affiliations

¹ Medical Clinic III for Oncology, Haematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.
² Institute of Neuropathology, University Hospital Bonn (UKB), Bonn, Germany.
³ Department of Radiology, University Hospital Bonn (UKB), Bonn, Germany.
⁴ Medical Clinic III, University Hospital Mannheim, Mannheim, Germany.

PMID: 24170029
DOI: 10.1038/leu.2013.320

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Brain Ischemia / chemically induced*
Fusion Proteins, bcr-abl / antagonists & inhibitors*
Fusion Proteins, bcr-abl / genetics
Humans
Imidazoles / adverse effects*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Middle Aged
Mutation
Protein Kinase Inhibitors / adverse effects*
Pyridazines / adverse effects*

Substances

Imidazoles
Protein Kinase Inhibitors
Pyridazines
ponatinib
Fusion Proteins, bcr-abl